The FAST 2 (Fourier-transform Infrared Spectroscopy guided Surfactant Therapy) trial begins in 4 Danish University [...]
The point-of-care device, which predicts severe lung disease in the ICU and NICU, has been CE [...]
Morten Henneveld, a life science executive with decades of commercial and operations experience, joins SIME [...]
Global neonatal key opinion leaders conclude that prediction of CLD at birth may prevent or [...]
First of its kind diagnostic for measuring surfactant in multifactorial Acute Respiratory Distress Syndrome (ARDS) [...]
LONDON, Nov. 11, 2020 /PRNewswire/ — SIME Clinical AI today announced that the European Patent Office intends [...]
A recent peer reviewed letter to editor by SIME has been published in Critical Care [...]
Innovative screening test has the potential to enable early preventative care for millions of babies [...]
Partnership will accelerate path to commercialisation of novel respiratory diagnostics LONDON, May 7, 2020 /PRNewswire/ — Today, [...]
Data demonstrating that AI accurately predicts Respiratory Distress Syndrome (RDS) in premature babies, enables company [...]
